Evidence map›Paper›PMID 39352615›Full record

ArticleEJNMMI research2024

Preclinical evaluation and first-in-human study of [

Shaoyu Liu, Ziqi Zhang, Jiawei Zhong, Huizhen Zhong, Yimin Fu, Lifang Liu, Xiaoting Ye, Xinlu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Clinical Evaluation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Clinical comprehensive evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shaoyu Liu *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.ORCID http://orcid.org/0000-0003-4960-8570
Ziqi Zhang *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Jiawei ZhongDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Huizhen ZhongDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Yimin FuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Lifang LiuNuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
Xiaoting YeNuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, China.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. 71lu@163.com.ORCID http://orcid.org/0000-0003-1997-5687

Funding

National Natural Science Foundation of China 82001879the Applied and Basic Research Foundation of Guangdong Province 2020A1515110159the Science and Technology Project of Guangzhou City 202102010252the Science and Technology Project of Guangzhou City 202201020558the Science and Technology Project of Guangzhou City 2024A03J1080the Zhongnanshan Medical Foundation of Guangdong Province ZNSA-2020003
6 · The paper itself

Abstract

backgroundFibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. [

results[

conclusionsBased on the physical imaging properties and longer half-life of [

trial registrationwww.Chictr.org.cn , ChiCTR2300076976 Retrospectively registered 25 October 2023. at, URL: https://www.chictr.org.cn/showproj.html?proj=206753 .

Indexed as

[18F]F-labeledFibroblast activation proteinPeptide-based FAP tracersPositron emission tomography

Identifiers

PMID39352615
PMCPMC11445204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.